{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:16:00Z","timestamp":1784042160677,"version":"3.55.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>A 63-year-old woman diagnosed with unresectable thymic carcinoma received modified ADOC therapy, followed by thoracic radiotherapy. Because she had a poor response to both chemotherapy and radiotherapy, lenvatinib was initiated at a dose of 24 mg once daily on day 1. The dose was reduced to 20 mg once daily on day 16.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The serum levels of lenvatinib and interleukin-6 (IL-6) alongside serum markers of heart failure and other lenvatinib-related adverse effects were monitored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The serum trough levels of lenvatinib on days 4 and 9 were both 108 ng\/mL. On day 25, the serum brain natriuretic peptide level and left ventricular ejection fraction were 2567 pg\/mL and 26%, respectively. Lenvatinib was discontinued on day 26, after which her serum brain natriuretic peptide levels decreased to 767 pg\/mL on day 30 and 27 pg\/mL on day 51. The toxicity threshold for the serum trough level of lenvatinib has been reported to be 88 ng\/mL. The patient had severe cancer inflammation due to carcinomatous pleurisy and tumor fever. The serum IL-6 levels during treatment ranged from 13.7 to 25.5 pg\/mL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>These findings suggest that elevated serum IL-6 levels lead to delayed elimination of lenvatinib. The increased serum levels of both lenvatinib and IL-6 may be associated with the development of acute heart failure in patients with thymic carcinoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001335","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T21:05:38Z","timestamp":1746479138000},"page":"584-586","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Serum Lenvatinib and Interleukin-6 Profiles and Their Relationship With Acute Heart Failure Development in a Patient With Thymic Carcinoma and Cancer Inflammation"],"prefix":"10.1097","volume":"47","author":[{"given":"Mitsutoshi","family":"Asakura","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Seki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Mino","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonobu","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-3789","authenticated-orcid":false,"given":"Takafumi","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"R1-20250912","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12032-019-1263-3","article-title":"Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer","volume":"36","author":"Nagahama","year":"2019","journal-title":"Med Oncol."},{"key":"R2-20250912","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-021-04286-2","article-title":"Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma","volume":"88","author":"Noda","year":"2021","journal-title":"Cancer Chemother Pharmacol."},{"key":"R3-20250912","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40261-014-0217-y","article-title":"Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults","volume":"34","author":"Shumaker","year":"2014","journal-title":"Clin Drug Investig."},{"key":"R4-20250912","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1124\/dmd.114.058073","article-title":"Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase","volume":"42","author":"Inoue","year":"2014","journal-title":"Drug Metab Dispos."},{"key":"R5-20250912","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.dmpk.2014.09.004","article-title":"Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4","volume":"30","author":"Mimura","year":"2015","journal-title":"Drug Metab Pharmacokinet."},{"key":"R6-20250912","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00228-016-2116-z","article-title":"Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients","volume":"72","author":"Sato","year":"2016","journal-title":"Eur J Clin Pharmacol."},{"key":"R7-20250912","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jpba.2015.05.008","article-title":"A validated LC\u2013MS\/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis","volume":"114","author":"Mano","year":"2015","journal-title":"J Pharm Biomed Anal."},{"key":"R8-20250912","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1124\/dmd.113.052225","article-title":"Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper","volume":"41","author":"Evers","year":"2013","journal-title":"Drug Metab Dispos."},{"key":"R9-20250912","doi-asserted-by":"crossref","first-page":"e018549","DOI":"10.1161\/JAHA.120.018549","article-title":"Interleukin 6 and development of heart failure with preserved ejection fraction in the general population","volume":"10","author":"Chia","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"R10-20250912","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5414\/CP201937","article-title":"Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers","volume":"52","author":"Shumaker","year":"2014","journal-title":"Int J Clin Pharmacol Ther."},{"key":"R11-20250912","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00228-020-02879-z","article-title":"Influences of ABC transporter and CYP3A4\/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects","volume":"76","author":"Li","year":"2020","journal-title":"Eur J Clin Pharmacol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:02:09Z","timestamp":1757678529000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001335","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"2025-01-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}